LMX1B
protein-codingLIM homeobox transcription factor 1 beta, the group of LIM class homeoboxes
Gene summary
This gene encodes a member of LIM-homeodomain family of proteins containing two N-terminal zinc-binding LIM domains, 1 homeodomain, and a C-terminal glutamine-rich domain. It functions as a transcription factor, and is essential for the normal development of dorsal limb structures, the glomerular basement membrane, the anterior segment of the eye, and dopaminergic and serotonergic neurons. Mutations in this gene are associated with nail-patella syndrome. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2010]
- NPS1
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~87.1 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0008061
Submitter: ClinGen
The LMX1B gene is located on chromosome 9 at 9q33.3 and encodes the LIM homeodomain transcription factor 1 beta, a transcription factor that plays a central role in cell differentiation during development. Mutations in LMX1B were first reported in relation to autosomal dominant nail-patella syndrome (NPS) in 1998 (Dreyer at al., 1998 PMID 9590287), although the first clinical description of the disorder was reported in 1933 (Turner JW, 1933 JAMA). The syndrome is characterised by a classic tetrad of congenital changes in the nails (absent, hypoplastic, or dystrophic), patellae (absent, small, or irregularly shaped), and elbows (limited range of motion), and the presence of iliac horns. Although not part of the classic tetrad, kidney disease and glaucoma also occur. While this disorder is highly penetrant, the expressivity of the clinical features is extremely variable both within and between families. More than 170 variants in LMX1B have been reported in NPS. onsense, frameshift, and splice site variants are observed throughout the entire gene, missense variants cluster predominantly in the LIM domains, and the the rest occur in the homeodomain. Partial and complete gene deletions have also been reported. 11 probands from 5 publications have been included in this curation (Dreyer at al., 1998 PMID 9590287; McIntosh et al., 1998 PMID 9837817; Sato et al., 2005 PMID 15774843; Bongers et al., 2008 PMID 18414507; Harita et al., 2020 PMID 32457516) to give a maximum score or 12 points for genetic evidence. . Additional evidence is available in the literature. This gene-disease association is also supported by experimental evidence, including animal models, expression studies, and in vitro functional assays. LMX1B was originally identified as a candidate gene for NPS due to the high degree of phenotypic similarity between lmx1b-knockout mice and humans with the disorder. Homozygous mice have absent patellae, absent nails, and renal abnormalities (Chen et al., 1998 PMID 9590288). Multiple studies examining the spatial and temporal expression pattern of LMX1B, using in situ hybridisation, have demonstrated its expression in the tissue types affected by NPS (Chen et al., 1998 PMID 9590288; Dreyer et al., 2000 PMID 10767331; Pressman et al., 2000 PMID 10660670). The mechanism of pathogenicity in NPS has been demonstrated to be loss of function, with mutated protein showing decreased or absent DNA binding ability and negligible transcriptional activity. No evidence has been observed to support a dominant-negative effect (Dreyer at al., 1998 PMID 9590287; Sato et al., 2005 PMID 15774843; Harita et al., 2020 PMID 32457516). Of note, variants in LMX1B have also been implicated in a renal-restricted nail-patella-like nephropathy. As per the criteria outlined by the ClinGen Lumping and Splitting Working Group, there was sufficient phenotypic variability and differences in the molecular mechanisms to support splitting these disorders into two distinct disease entities; nail-patella syndrome (OMIM: 161200) and focal segmental glomerulosclerosis 10 (OMIM:256020). Autosomal dominant focal segmental glomerulosclerosis 10 has therefore been curated separately. In summary, LMX1B is definitively associated with autosomal dominant nail-patella syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Syndromic Disorders Gene Curation Expert Panel on the meeting date February 3rd, 2021 (SOP Version 8).
Inheritance Pattern: AD
Disease ID:MONDO:0008061
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0008061
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0008061
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0008061
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0009724
Submitter: Orphanet
Clinical Genomic Database (CGD)
Manifestation: Dermatologic; Musculoskeletal; Ophthalmologic; Renal
Intervention: Ophthalmologic; Pharmacogenomic; Renal
Rationale: In Nail-patella syndrome, individuals may have open-angle glaucoma, and surveillance and appropriate treatment may be beneficial; Agents that may contribute to glaucoma (as well as NSAIDs as relates to renal function) should be avoided; Medical treatment (eg, ACE inhibitors) may be beneficial in terms of affecting the progression of renal disease; Renal transplantation has been described; In Focal segmental glomerulosclerosis, recognition of disease may allow early management, and renal transplant has been described
Comments: Onset may typically be during adulthood, though surveillance earlier may be warranted given reports of affected individuals in the 3rd decade
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to LMX1B variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001174147.2. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 5 | 101 | 3 | 109 | ||
| missense | 20 | 30 | 171 | 19 | 240 | |
| nonsense | 37 | 8 | 45 | |||
| start loss | 0 | |||||
| frameshift | 34 | 15 | 1 | 50 | ||
| splice donor/acceptor (+/-2bp) | 14 | 4 | 4 | 1 | 23 | |
| Total | 105 | 57 | 181 | 121 | 3 | 467 |
Highest pathogenic variant AF is 0.000038558144
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001167618.1 | 8 | MANE Select | |
| Ensembl | ENSP00000362573.3 | 8 | MANE Select | |
| RefSeq | NP_001167617.1 | 8 | Standard | |
| RefSeq | NP_002307.2 | 8 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| lmx1ba | Danio rerio | Structure: glutamatergic neuron Quality: decreased amount abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Primary Focal Segmental Glomerulosclerosis FSGS
- Dopaminergic Neurogenesis
- Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways
Biological Process
- in utero embryonic development
- regulation of transcription, DNA-templated
- multicellular organism development
- dorsal/ventral pattern formation
- neuron differentiation
Molecular Function
- RNA polymerase II regulatory region sequence-specific DNA binding
- DNA-binding transcription factor activity, RNA polymerase II-specific
- DNA-binding transcription factor activity
- protein binding
- metal ion binding
Cellular Component
- nucleus
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000355497
- Coding exons
- 8
- Length
- 86590
- Individuals with no LoFs
- 125704
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 3
- Defined
- 125707
- p
- 0.0000119
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.02 | 169 | 261 | 0.648 | 0.0000168 | 2624 |
| Missense (PolyPhen) | 43 | 99.872 | 0.43055 | 1013 | ||
| Synonymous | -0.810 | 128 | 117 | 1.10 | 0.00000854 | 759 |
| Loss of Function | 3.56 | 4 | 22.1 | 0.181 | 0.00000120 | 214 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0.000088 | 0.000087 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0 | 0.0 | absent |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Essential for the specification of dorsal limb fate at both the zeugopodal and autopodal levels.;
Recessive Scores
- pRec
- 0.350
Intolerance Scores
- LoFtool
- 0.0982
- RVIS EVS
- -0.85
- RVIS percentile EVS
- 11.06
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.980
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |